The 10-year verdict in plain numbers

For anyone weighing these two procedures, the most pressing question is straightforward: which one is more likely to still be working a decade from now? On that question, the strongest available evidence points firmly in one direction.

The Gudas et al. prospective randomised controlled trial followed 60 young athletes for ten years and recorded a 14% failure rate for mosaicplasty against a 38% failure rate for microfracture — a gap that is both statistically significant and clinically meaningful. Functional scores on the ICRS and IKDC scales remained substantially higher in the mosaicplasty group at that ten-year mark, with no sign that the advantage was narrowing. A subsequent randomised study extending follow-up to 15–17 years confirmed the same pattern: mosaicplasty continued to hold its structural and functional lead over microfracture at the longest time horizon yet reported.

This matters for how you weigh the evidence. These are not registry estimates or retrospective case series — the Gudas study is a real prospective RCT conducted in athletes, which places it at the top of the evidence hierarchy for cartilage repair comparisons at this time horizon.

The plain reading: for patients who intend to remain physically active over the next decade, mosaicplasty holds up; microfracture, for a meaningful proportion of patients, increasingly does not.

Why microfracture breaks down over time

The gap in those failure rates has a biological explanation — and understanding it helps clarify why the divergence is structural rather than a question of surgical technique.

Microfracture works by puncturing the subchondral bone beneath a cartilage defect so that marrow-derived stem cells can migrate into the void and form a repair layer. The tissue that results is fibrocartilage: a type I collagen matrix that is closer in character to scar tissue than to the native type II hyaline cartilage that articulating joint surfaces are built from. Hyaline cartilage is precisely engineered for repetitive compressive loading — it is stiffer, more resilient, and better integrated with the underlying bone. Fibrocartilage is not. A useful analogy is patching a road with gravel rather than tarmac: both fill the hole, both provide early relief, but under sustained heavy traffic the gravel shifts and breaks down progressively.

This is exactly the deterioration pattern the evidence captures. A 10-year randomised controlled trial comparing matrix-augmented microfracture (AMIC®) with standalone microfracture found that both groups improved in the first two years — then microfracture scores declined significantly and progressively, while the augmented group remained stable. A 2024 systematic review reached a similar conclusion, finding that microfracture has limited long-term efficacy for medium-to-large defects at mean follow-up of ten years or more.

There is a further downstream consequence worth noting: the microfracture technique itself damages the subchondral bone plate, which may compromise the viability of future cartilage repair procedures if the initial repair fails.

Historically, microfracture occupied an important clinical niche when better-evidenced alternatives were not widely available. For patients returning to high-impact activity over a decade, however, the biology works against it — a pattern that shows up clearly when large patient cohorts are followed over time, as the survival data discussed next illustrates.

What survival curves show across larger populations

Cohort data from a larger real-world population makes the divergence even harder to ignore. Solheim et al. (2018, Cartilage journal) tracked 119 patients who had microfracture and 84 who had mosaicplasty, applying Kaplan-Meier survival analysis to compare how long each repair held before clinical failure.

The overall failure rates — 66% for microfracture versus 51% for mosaicplasty (p=0.01) — confirm the direction established in the RCT, now across a broader patient group. The statistic that most plainly conveys the practical difference is median time to failure: 4.0 years for microfracture against 8.4 years for mosaicplasty. A patient whose microfracture repair fails at the median point is already in difficulty before many return-to-sport programmes have reached their intended endpoint.

The underlying survival figures are equally striking. Mosaicplasty held above 80% repair survival for the first seven years and above 60% at fifteen years. Microfracture fell below 80% within the first twelve months — meaning, for a substantial portion of this cohort, early deterioration was detectable before their first annual review — and below 60% within three years. At the point where the microfracture curve crosses 60%, the mosaicplasty curve has barely begun its more gradual decline.

Those figures come from a mixed patient population. Whether the same pattern holds for athletes returning to high-impact sport is where the evidence turns next.

Outcomes for athletes and sport return

For most active patients, the headline figure from the largest sport-specific mosaicplasty series is genuinely encouraging. Among 61 football players followed for a mean of 9.6 years (range 2–17 years), Panics et al. recorded 89% good-to-excellent outcomes on the ICRS scoring system — a scale designed to reflect real-world joint function rather than simply pain relief.

Return to sport followed a similar pattern: 67% of all players in the series returned to the same level of competition as before injury. Among elite players specifically, that figure rose to 89%. Mean time back to competitive play was 4.5 months — a figure that matters enormously to anyone planning around a season, a race calendar, or a training block.

The data also point clearly to which patients do best. Younger athletes with smaller lesions saw significantly better outcomes than older patients with larger defects. Lesion location matters too: repairs to the medial and lateral femoral condyles produced significantly better results than those at the patella or trochlea. A 2024 review of long-term autologous osteochondral transfer outcomes corroborated this, concluding that appropriately selected patients — matched by age, lesion size, location, and underlying cause — achieve favourable long-term function and avoid joint replacement at high rates.

These figures reflect selected series rather than universal guarantees. A consultant assessment remains the appropriate route for establishing whether an individual's specific lesion, activity level, and anatomy make mosaicplasty a realistic pathway.

Who mosaicplasty suits — and where the limits are

Mosaicplasty is not the right answer for every cartilage defect, and understanding where its boundaries lie is as important as knowing its strengths.

The primary constraint is donor availability. Grafts are harvested from a lower-demand area of the patient's own knee, which limits the total surface area that can be reliably filled. The procedure works best for focal lesions under 3–4 cm²; beyond that threshold, alternatives such as MACI, ACI, or fresh osteochondral allograft (OCA) become more appropriate options.

At the smaller end of the scale, the evidence does not demand mosaicplasty for every lesion. For defects under 2.5 cm² — particularly in patients whose activity level is moderate rather than competitive — microfracture remains a reasonable first-line choice. It is less surgically demanding and carries a faster rehabilitation pathway. The 10-year failure data becomes most consequential when the patient is young, physically active, and facing a lesion large enough for fibrocartilage breakdown to translate into clinical deterioration.

Donor-site morbidity deserves honest mention before any decision is made. Harvest-site discomfort is common in the short term and persists in a minority of patients; it is generally modest, but it is a real trade-off, separate from the index-joint symptoms that prompted surgery in the first place.

The evidence base itself has limits worth stating plainly. Most long-term data concern femoral condyle lesions in the knee; outcomes for patellar, trochlear, or talar defects are considerably less well characterised. The studies supporting mosaicplasty's advantage — including the Gudas RCT and the Solheim cohort — are among the stronger examples of long-term cartilage repair evidence, but neither was a large multi-centre trial. The direction of benefit is consistent across them; the degree of benefit in any individual case requires clinical assessment of defect size, location, age, and activity demand together.

Getting assessed and taking the next step

Across a decade of follow-up, the evidence consistently favours mosaicplasty for active patients with focal lesions above roughly 2.5 cm² — particularly those who need to return to high-impact sport and want repair tissue capable of sustaining that load long-term. The decision turns on defect size, location, age, and activity demand together, and requires imaging review by a consultant experienced in cartilage repair.

MSK Doctors offers consultant-led cartilage assessments at Sleaford (NG34) and Grantham (NG31), with no GP referral or NHS-style waiting list — book directly at mskdoctors.com.

1. [1] Long-Term Survival after Microfracture and Mosaicplasty for Knee Articular Cartilage Repair: A Comparative Study Between Two Treatments Cohorts. (2018). https://doi.org/10.1177/1947603518783482 https://doi.org/10.1177/1947603518783482
2. [2] Randomized Study of Long-term (15-17 Years) Outcome After Microfracture Versus Mosaicplasty in Knee Articular Cartilage Defects. (2018). https://doi.org/10.1177/0363546517745281 https://doi.org/10.1177/0363546517745281
3. [3] Long-Term Outcomes of Autologous Osteochondral Transfer of the Knee Are Successful and Predicated Upon Appropriate Patient Selection. (2024). https://doi.org/10.1016/j.arthro.2024.03.012 https://doi.org/10.1016/j.arthro.2024.03.012
4. [4] Microfracture for medium size to large knee chondral defects has limited long-term efficacy: A systematic review. (2024). https://doi.org/10.1002/jeo2.70060 https://doi.org/10.1002/jeo2.70060
5. [5] A Retrospective Analysis in the Management of Osteochondral Lesions of the Talus: Microfracture Versus Mosaicplasty. (2024). https://doi.org/10.5455/annalsmedres.2023.12.333 https://doi.org/10.5455/annalsmedres.2023.12.333